EFFECTS OF NF-kB SIGNALING INHIBITORS ON BED BUG RESISTANCE TO ORALLY PROVISIONED ENTOMOPATHOGENIC BACTERIA
Abstract:
Treatment compositions for controlling bed bugs and methods of use, including reducing bed bug resistance to a biological control agent are disclosed. The treatment compositions can include both a NF-kB signaling inhibitor and biological control agent, such as, an entomopathogenic bacteria, to improve the treatment composition efficacy against bed bugs. Provisioning of a small molecule inhibitor of NF-kB signaling can increase the rate of bed bug mortality during infection with a bacterial entomopathogen. Increased mortality can be independent of direct effects of the inhibitor on bacterial growth and can be instead the result of a reduced ability of bed bugs to clear the infection when treated with the inhibitor.
Information query
Patent Agency Ranking
0/0